PERSPECTIVE

5315 Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Despina Siolos and Gregory J. Hannon

5315 Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Despina Siolos and Gregory J. Hannon

MOLECULAR AND CELLULAR PATHOBIOLOGY

5371 Candidate Tumor Suppressor and pVHL Partner Jade-1 Binds and Inhibits AKT in Renal Cell Carcinoma
Liling Zeng, Ming Bai, Amit K. Mittal, Wassim El-Jouni, Jing Zhou, David M. Cohen, Mina I. Zhou, and Herbert T. Cohen

Precis: These findings identify an important new candidate biomarker in renal cell carcinoma that functions in tumor suppression as a key negative modifier of AKT signaling, with potentially broader implications in human cancer.
**Notch1-Induced Brain Tumor Models**
**the Sonic Hedgehog Subgroup of Human Medulloblastoma**
Sivaraman Natarajan, Yaochen Li, Emily E. Miller, David J. Shih, Michael D. Taylor, Timothy M. Stearns, Roderick T. Bronson, Susan L. Ackerman, Jeong K. Yoon, and Kyuson Yun

*Précis:* This study is the first to clearly demonstrate the oncogenic potential of activated Notch1 and in doing so establishes a novel mouse model of medulloblastoma.

---

**Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy**
Frédérique Végran, Romain Mary, Anne Gibeaud, Céline Mirjolet, Bertrand Collin, Alexandra Oudot, Céline Charon-Barra, Laurent Arnould, Sarab Lizard-Nacol, and Romain Boidot

*Précis:* Cancer-specific alternate splicing that occurs in the cell death inhibitor survivin generates a potent mediator of resistance against immune-mediated or chemotherapeutic killing.

---

**miR-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Non–Small Cell Lung Cancer**
Junchao Cai, Lishan Fang, Yongbo Huang, Rong Li, Jie Yuan, Yi Yang, Xun Zhu, Baixue Chen, Jueheng Wu, and Mengfeng Li

*Précis:* These results reveal how AKT becomes activated in lung adenocarcinoma, identifying a pivotal role for an oncomir of emerging importance in the development and progression of this widespread disease.

---

**FOX1L1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer**
Geng Zhang, Peijun He, Jochen Gaedcke, B. Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Nader Hanna, H. Richard Alexander, and S. Perwez Hussain

*Précis:* FOX transcription factors continue to emerge as central determinants of cancer pathophysiology and patient outcomes in many deadly human solid tumors, illustrated in this study of FOX1L1 in pancreatic cancer.

---

**PTK6 Activation at the Membrane Regulates Epithelial–Mesenchymal Transition in Prostate Cancer**
Yu Zheng, Zebin Wang, Wenjun Bie, Patrick M. Brauer, Bethany E. Perez White, Jing Li, Veronique Nogueira, Pradip Raychaudhuri, Nissim Hay, Debra A. Tometti, Virgilia Macias, André Kajdacsy-Balla, and Angela L. Tyner

*Précis:* Membrane relocalization and activation of the nonreceptor tyrosine kinase PTK6 serves as a novel marker for prostate cancer staging and prognosis, also offering potential therapeutic implications for treatment of prostate cancer.

---

**Myoferlin Is a Key Regulator of EGFR Activity in Breast Cancer**
Andrei Turtoi, Arnaud Blomme, Akeila Bellahcene, Christine Gilles, Vincent Hennequère, Paul Peixoto, Elettra Bianchi, Agnès Noel, Edwin De Pauw, Eric Lifrange, Philippe Delvenne, and Vincent Castronovo

*Précis:* Given the therapeutic significance of EGFR targeting, this study’s findings highlight a rational candidate function to target for future drug development.

---

**HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ERα and Inducing IL-6 Expression**
Nilay Shah, Kideok Jin, Leigh-Ann Cruz, Sunju Park, Helen Sadik, Soonweng Cho, Chirayu Pankaj Goswami, Harikrishna Nalafshari, Rajnish Gupta, Howard Y. Chang, Zhe Zhang, Ashley Cimino-Mathews, Leslie Cope, Christopher Umbricht, and Saraswati Sukumar

*Précis:* These results establish a function for the homeodomain transcription factor HOXB13 in the emergence of tamoxifen resistance in breast cancer through direct blockade of ERα and upregulation of the IL-6 pathway.

---

**Inhibition of AMPK and Krebs Cycle Gene Expression Drives Metabolic Remodeling of Pten-Deficient Prenoeplastic Thyroid Cells**
Valeria G. Antico Arciuch, Marika A. Russo, Kristy S. Kang, and Antonio Di Cristofano

*Précis:* This study describes a novel mechanism of glycolytic upregulation that is distinct from the Warburg effect and mediated by PI3K-dependent inactivation of the core metabolic kinase AMPK, with potentially great impact on understanding a central metabolic question in cancer.
**PREVENTION AND EPIDEMIOLOGY**

5473 | Chemopreventive Activity of Plant Flavonoid Isorhamnetin in Colorectal Cancer Is Mediated by Oncogenic Src and β-Catenin

Shakir M. Saud, Matthew R. Young, Yawa L. Jones-Hall, Lilia Ileva, Moses O. Evbuomwan, Jennifer Wise, Nancy H. Colburn, Young S. Kim, and Gerd Bobe

*Précis:* This study advances mechanistic understanding for the anticancer properties of a natural flavonoid that can prevent tumorigenesis, reverse EMT, and block metastasis with limited toxicity in various types of cancer.

5519 | AC1MMYR2, an Inhibitor of Dicer-Mediated Biogenesis of Oncomir miR-21, Reverses Epithelial–Mesenchymal Transition and Suppresses Tumor Growth and Progression

Zhendong Shu, Junxia Zhang, Xiaomin Qian, Lei Han, Kaailiang Zhang, Luyue Chen, Jilong Liu, Yu Ren, Ming Yang, Anling Zhang, Peiyu Pu, and Chunsheng Kang

*Précis:* This study offers a novel, high-throughput method to screen for small-molecule inhibitors of microRNA maturation and presents an inhibitor of oncomir miR-21 maturation as a candidate antitumor drug.

**THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY**

5485 | Novel Small-Molecule Inhibitors of Bel- XL to Treat Lung Cancer

Dongkyoo Park, Andrew T. Magis, Rui Li, Taoleek K. Owonikoko, Gabriel L. Sica, Shi-Yong Sun, Suresh S. Ramalingam, Fadlo R. Khuri, Walter J. Curran, and Xingming Deng

*Précis:* The new class of Bel- XL inhibitors identified in this report exhibits distinct specificities and strong potency against lung cancer and acquired radioresistance in this setting.

5489 | AC1MMYR2, an Inhibitor of Dicer-Mediated Biogenesis of Oncomir miR-21, Reverses Epithelial–Mesenchymal Transition and Suppresses Tumor Growth and Progression

Zhendong Shu, Junxia Zhang, Xiaomin Qian, Lei Han, Kaailiang Zhang, Luyue Chen, Jilong Liu, Yu Ren, Ming Yang, Anling Zhang, Peiyu Pu, and Chunsheng Kang

*Précis:* This study offers a novel, high-throughput method to screen for small-molecule inhibitors of microRNA maturation and presents an inhibitor of oncomir miR-21 maturation as a candidate antitumor drug.

5497 | Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway


*Précis:* These findings advance our understanding of cellular resistance to DNA crosslinking agent used to combat cancer, implicating the WRN helicase as a target for inhibition in cells defective in the Fanconi anemia pathway of DNA repair targeted by certain chemotherapy strategies.

5497 | Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway


*Précis:* These findings advance our understanding of cellular resistance to DNA crosslinking agent used to combat cancer, implicating the WRN helicase as a target for inhibition in cells defective in the Fanconi anemia pathway of DNA repair targeted by certain chemotherapy strategies.

**TUMOR AND STEM CELL BIOLOGY**

5508 | A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1

Takahiro Oike, Hideaki Ogihara, Yuichi Tominaga, Kentaro Ito, Osamu Ando, Koji Tsuta, Tatsuji Mizukami, Yoko Shimada, Hisanori Isozuma, Mayumi Komachi, Koh Furuta, Shun-Ichi Watanabe, Takashi Nakano, Jun Yokota, and Takashi Kohno

*Précis:* These results offer a rationale for an epigenetic-based treatment of many lung cancers and other common cancers lacking known therapeutic gene mutations, providing a broad catchment strategy for treatment.

5544 | SOX2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma

Petra M. Bareiss, Anna Paczulla, Hui Wang, Rebekka Schairer, Stefan Wiehr, Ursula Kohlhofer, Oliver C. Rothfuss, Anna Fischer, Sven Perner, Annette Staeble, Diethelm Wallwiener, Falko Fend, Tanja Fehm, Bernd Pichler, Lothar Kanz, Leticia Quintanilla-Martinez, Klaus Schulze-Osthoff, Frank Essmann, and Claudia Lengerker

*Précis:* The embryonic protein SOX2, which serves as a cancer stem cell marker in a variety of cancers, is shown here to induce the tumor-initiating capacity of serous ovarian carcinoma cells.

5556 | Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells

MyLinH T. Duong, Said Akli, Sira Macalou, Anna Biernacka, Bistra G. Debebe, Min Yi, Kelly K. Hunt, and Khandan Keyomarsi

*Précis:* The increased oncogenic potency of cyclin E proteolytic cleavage products, which accumulate in some breast cancers, relates to their ability to promote EMT and cancer stem-like properties, the mechanistic aspects of which have immediate therapeutic implications.
MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin M. Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Kufe, and David Avigan

**Précis:** A mucin gene widely upregulated in solid cancers and studied as an immunotherapeutic target is reported here to serve as a leukemia stem cell marker, broadening interest in its potential uses to better define or eradicate malignancy.

C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells via Modulating MET Glycosylation and Dimerization

Yao-Ming Wu, Chiung-Hui Liu, Miao-Juei Huang, Hong-Shiee Lai, Po-Huang Lee, Rey-Heng Hu, and Min-Chuan Huang

**Précis:** These findings offer evidence in support of an O-glycosyl transferase as an appealing therapeutic target to develop for treatment of liver cancer.

Distinct FAK Activities Determine Progenitor and Mammary Stem Cell Characteristics

Ming Lao, Xiaofeng Zhao, Song Chen, Suling Liu, Max S. Whicha, and Jun-Lin Guan

**Précis:** These findings define distinct kinase-dependent and kinase-independent activities of the FAK kinase that permit therapeutic strategies to address cancer heterogeneity more effectively, a major challenge for molecular targeted therapeutics generally.

Correction: Cancer Angiogenesis Induced by Kaposi’s Sarcoma-Associated Herpesvirus Is Mediated by EZH2

Correction: Emil Frei III, MD: In Memoriam (1924–2013)

**ABOUT THE COVER**

The tumor microenvironment contains numerous cellular elements, such as cancer-associated fibroblasts (CAF) and activated myofibroblasts that participate in fibrovascular, vascular, and chem/o cytokine support of tumors. Using bone marrow transplant recipient mice harboring CD44 knockout (KO) mesenchymal stem cells (MSC), the precursor population for CAFs and myofibroblasts, Spaeth and colleagues observed the inability of engrafted CD44-KO stromal cells to provide tumor support, to generate vascular support, and importantly, to transition from the benign MSC phenotype to the tumor-supportive aggressive myofibroblast phenotype. The spectrally unmixed image displays smooth muscle actin + CAFs and myofibroblasts (red) from bone marrow derived CD44-KO (green) MSC in the tumor microenvironment. For details, see article by Spaeth and colleagues on page 5347.
Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/73/17

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.